SEGMENTS

3 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

SEGMENTS

11. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic subsidiary. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI, consisting of patent maintenance costs.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not have any revenues or activities other than patent maintenance. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Three Months Ended June 30,
	2022			2021
Revenues:
Aethlon	$	–		$	131,966
ESI		–			–
Total Revenues	$	–		$	131,966
Operating Losses:
Aethlon	$	(2,904,014	)	$	(2,092,763	)
ESI		(2,067	)		(5,675	)
Total Operating Loss	$	(2,906,081	)	$	(2,098,438	)
Net Losses:
Aethlon	$	(2,904,014	)	$	(2,092,763	)
ESI		(2,067	)		(5,675	)
Net Loss Before Non-Controlling Interests	$	(2,096,081	)	$	(2,098,438	)
Depreciation and Amortization:
Aethlon	$	30,650		$	11,666
ESI		–			–
Total Depreciation and Amortization	$	30,650		$	11,666
Capital Expenditures:
Aethlon	$	41,169		$	38,374
ESI		–			–
Capital Expenditures	$	41,169		$	38,374

		June 30, 2022		June 30, 2021
Cash:
Aethlon	$	14,921,578	$	25,171,482
ESI		197		197
Total Cash	$	14,921,775	$	25,171,679
Total Assets:
Aethlon	$	17,132,021	$	25,866,814
ESI		197		197
Total Assets	$	17,132,218	$	25,867,011